Cancer prevalence in Central Europe

The EROPREVAL Study

J. M. Lutz, S. Francisci, E. Mugno, M. Usel, V. Pompe-Kirn, J. W. Coebergh, M. Bieslka-Lasota, W. Oberaigner, H. Storm, G. Engholm, T. Aareleid, T. Hakulinen, G. Hédelin, H. Lefevre, J. Mace-Lesec'h, J. Faivre, G. Chaplain, P. M. Carli, P. Arveux, J. Estève & 73 others M. Colonna, N. Raverdy, P. Jun, J. Michaelis, H. Ziegler, C. Stegmaier, H. Tulinius, R. Capocaccia, I. Corazziari, R. De Angelis, S. Francisci, S. Hartley, F. Valente, A. Verdecchia, A. Zappone, F. Berrino, G. Gatta, A. Micheli, E. Mugno, M. Sant, P. Crosignani, E. Conti, M. Vercelli, C. Casella, A. Puppo, M. Federico, M. Ponz De Leon, V. De Lisi, R. Zanetti, C. Magnani, L. Gafà, F. Falcini, E. Paci, E. Crocetti, S. Guzzinati, J. Rachtan, M. Bielska-Lasota, I. Plesko, V. Pompe-Kirn, I. Izarzugaza, A. Izquierdo, C. Martinez-Garcia, I. Garau, E. Ardanaz, C. Moreno, J. Galceran, V. Moreno, T. Möller, H. Anderson, J. Torhorst, C. Bouchardy, J. M. Lutz, M. Usel, J. E. Dowd, J. W W Coebergh, M. Janssen-Heijnen, R. A M Damhuis, R. Black, V. Harris, D. Stockton, T. W. Davies, M. P. Coleman, S. Harris, E. M I Williams, D. Forman, R. Iddenden, M. J. Quinn, M. Roche, J. Smith, H. Moller, P. Silcocks, G. Lawrence, K. Hemmings

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Background: Information on cancer prevalence is either absent or largely unavailable for central European countries. Materials and methods: Austria, Germany, The Netherlands, Poland, Slovakia, Slovenia and Switzerland cover a population of 13 million inhabitants. Cancer registries in these countries supplied incidence and survival data for 465 000 cases of cancer. The prevalence of stomach, colon, rectum, lung, breast, cervix uteri, corpus uteri and prostate cancer, as well as skin melanoma, Hodgkin's disease, leukaemia and all malignant neoplasms combined was estimated for the end of 1992. Results: A large heterogeneity was observed within central European countries. For all cancers combined, estimates ranged from 730 per 100 000 in Poland (men) to 3350 per 100 000 in Germany (women). Overall cancer prevalence was the highest in Germany and Switzerland, and the lowest in Poland and Slovenia. In Slovakia, prevalence was higher than average for men and lower than average for women. This was observed for almost all ages. As shown by incidence data, breast cancer was the most frequent malignancy among women in all countries. Among men, prostate cancer was the leading malignancy in Germany, Austria and Switzerland, and lung cancer was the major cancer in Slovenia, Slovakia and Poland. The Netherlands had a high prevalence of both prostate and lung cancer. Time-related magnitude of prevalence within each country and the variability of such proportions across the countries has been estimated and cancer prevalence is given by time since diagnosis (1 year, 1-5 years, 5-10 years, >10 years) for each site. The weight of 1-year prevalence (248 per 100 000 among men and 253 per 100 000 among women) was 10 years before), reflecting long-term survival, and number of people considered as cured from cancer were 490 per 100 000 for men and 1028 per 100 000 for women, with a range between 26% (The Netherlands, men) and 50% (Slovakia, women). Conclusion: It is clear from observing countries in Central Europe, that high cancer prevalence is associated with well-developed economies. This burden of cancer could be interpreted as a paradoxical effect of better treatments and thereby survival. It could also be taken as a sign for not being satisfied with the advances in treating patients diagnosed with cancer, and for supporting more primary prevention.

Original languageEnglish
Pages (from-to)313-322
Number of pages10
JournalAnnals of Oncology
Volume14
Issue number2
DOIs
Publication statusPublished - Feb 1 2003

Fingerprint

Neoplasms
Slovakia
Poland
Slovenia
Germany
Switzerland
Netherlands
Prostatic Neoplasms
Austria
Survival
Lung Neoplasms
Uterine Neoplasms
Incidence
Primary Prevention
Hodgkin Disease
Rectum
Cervix Uteri
Registries
Melanoma
Stomach

Keywords

  • Cancer registries
  • Central Europe
  • Prevalence

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Lutz, J. M., Francisci, S., Mugno, E., Usel, M., Pompe-Kirn, V., Coebergh, J. W., ... Hemmings, K. (2003). Cancer prevalence in Central Europe: The EROPREVAL Study. Annals of Oncology, 14(2), 313-322. https://doi.org/10.1093/annonc/mdg059

Cancer prevalence in Central Europe : The EROPREVAL Study. / Lutz, J. M.; Francisci, S.; Mugno, E.; Usel, M.; Pompe-Kirn, V.; Coebergh, J. W.; Bieslka-Lasota, M.; Oberaigner, W.; Storm, H.; Engholm, G.; Aareleid, T.; Hakulinen, T.; Hédelin, G.; Lefevre, H.; Mace-Lesec'h, J.; Faivre, J.; Chaplain, G.; Carli, P. M.; Arveux, P.; Estève, J.; Colonna, M.; Raverdy, N.; Jun, P.; Michaelis, J.; Ziegler, H.; Stegmaier, C.; Tulinius, H.; Capocaccia, R.; Corazziari, I.; De Angelis, R.; Francisci, S.; Hartley, S.; Valente, F.; Verdecchia, A.; Zappone, A.; Berrino, F.; Gatta, G.; Micheli, A.; Mugno, E.; Sant, M.; Crosignani, P.; Conti, E.; Vercelli, M.; Casella, C.; Puppo, A.; Federico, M.; Ponz De Leon, M.; De Lisi, V.; Zanetti, R.; Magnani, C.; Gafà, L.; Falcini, F.; Paci, E.; Crocetti, E.; Guzzinati, S.; Rachtan, J.; Bielska-Lasota, M.; Plesko, I.; Pompe-Kirn, V.; Izarzugaza, I.; Izquierdo, A.; Martinez-Garcia, C.; Garau, I.; Ardanaz, E.; Moreno, C.; Galceran, J.; Moreno, V.; Möller, T.; Anderson, H.; Torhorst, J.; Bouchardy, C.; Lutz, J. M.; Usel, M.; Dowd, J. E.; Coebergh, J. W W; Janssen-Heijnen, M.; Damhuis, R. A M; Black, R.; Harris, V.; Stockton, D.; Davies, T. W.; Coleman, M. P.; Harris, S.; Williams, E. M I; Forman, D.; Iddenden, R.; Quinn, M. J.; Roche, M.; Smith, J.; Moller, H.; Silcocks, P.; Lawrence, G.; Hemmings, K.

In: Annals of Oncology, Vol. 14, No. 2, 01.02.2003, p. 313-322.

Research output: Contribution to journalArticle

Lutz, JM, Francisci, S, Mugno, E, Usel, M, Pompe-Kirn, V, Coebergh, JW, Bieslka-Lasota, M, Oberaigner, W, Storm, H, Engholm, G, Aareleid, T, Hakulinen, T, Hédelin, G, Lefevre, H, Mace-Lesec'h, J, Faivre, J, Chaplain, G, Carli, PM, Arveux, P, Estève, J, Colonna, M, Raverdy, N, Jun, P, Michaelis, J, Ziegler, H, Stegmaier, C, Tulinius, H, Capocaccia, R, Corazziari, I, De Angelis, R, Francisci, S, Hartley, S, Valente, F, Verdecchia, A, Zappone, A, Berrino, F, Gatta, G, Micheli, A, Mugno, E, Sant, M, Crosignani, P, Conti, E, Vercelli, M, Casella, C, Puppo, A, Federico, M, Ponz De Leon, M, De Lisi, V, Zanetti, R, Magnani, C, Gafà, L, Falcini, F, Paci, E, Crocetti, E, Guzzinati, S, Rachtan, J, Bielska-Lasota, M, Plesko, I, Pompe-Kirn, V, Izarzugaza, I, Izquierdo, A, Martinez-Garcia, C, Garau, I, Ardanaz, E, Moreno, C, Galceran, J, Moreno, V, Möller, T, Anderson, H, Torhorst, J, Bouchardy, C, Lutz, JM, Usel, M, Dowd, JE, Coebergh, JWW, Janssen-Heijnen, M, Damhuis, RAM, Black, R, Harris, V, Stockton, D, Davies, TW, Coleman, MP, Harris, S, Williams, EMI, Forman, D, Iddenden, R, Quinn, MJ, Roche, M, Smith, J, Moller, H, Silcocks, P, Lawrence, G & Hemmings, K 2003, 'Cancer prevalence in Central Europe: The EROPREVAL Study', Annals of Oncology, vol. 14, no. 2, pp. 313-322. https://doi.org/10.1093/annonc/mdg059
Lutz JM, Francisci S, Mugno E, Usel M, Pompe-Kirn V, Coebergh JW et al. Cancer prevalence in Central Europe: The EROPREVAL Study. Annals of Oncology. 2003 Feb 1;14(2):313-322. https://doi.org/10.1093/annonc/mdg059
Lutz, J. M. ; Francisci, S. ; Mugno, E. ; Usel, M. ; Pompe-Kirn, V. ; Coebergh, J. W. ; Bieslka-Lasota, M. ; Oberaigner, W. ; Storm, H. ; Engholm, G. ; Aareleid, T. ; Hakulinen, T. ; Hédelin, G. ; Lefevre, H. ; Mace-Lesec'h, J. ; Faivre, J. ; Chaplain, G. ; Carli, P. M. ; Arveux, P. ; Estève, J. ; Colonna, M. ; Raverdy, N. ; Jun, P. ; Michaelis, J. ; Ziegler, H. ; Stegmaier, C. ; Tulinius, H. ; Capocaccia, R. ; Corazziari, I. ; De Angelis, R. ; Francisci, S. ; Hartley, S. ; Valente, F. ; Verdecchia, A. ; Zappone, A. ; Berrino, F. ; Gatta, G. ; Micheli, A. ; Mugno, E. ; Sant, M. ; Crosignani, P. ; Conti, E. ; Vercelli, M. ; Casella, C. ; Puppo, A. ; Federico, M. ; Ponz De Leon, M. ; De Lisi, V. ; Zanetti, R. ; Magnani, C. ; Gafà, L. ; Falcini, F. ; Paci, E. ; Crocetti, E. ; Guzzinati, S. ; Rachtan, J. ; Bielska-Lasota, M. ; Plesko, I. ; Pompe-Kirn, V. ; Izarzugaza, I. ; Izquierdo, A. ; Martinez-Garcia, C. ; Garau, I. ; Ardanaz, E. ; Moreno, C. ; Galceran, J. ; Moreno, V. ; Möller, T. ; Anderson, H. ; Torhorst, J. ; Bouchardy, C. ; Lutz, J. M. ; Usel, M. ; Dowd, J. E. ; Coebergh, J. W W ; Janssen-Heijnen, M. ; Damhuis, R. A M ; Black, R. ; Harris, V. ; Stockton, D. ; Davies, T. W. ; Coleman, M. P. ; Harris, S. ; Williams, E. M I ; Forman, D. ; Iddenden, R. ; Quinn, M. J. ; Roche, M. ; Smith, J. ; Moller, H. ; Silcocks, P. ; Lawrence, G. ; Hemmings, K. / Cancer prevalence in Central Europe : The EROPREVAL Study. In: Annals of Oncology. 2003 ; Vol. 14, No. 2. pp. 313-322.
@article{70583ca2dbd34c389fd5115f6b3e0727,
title = "Cancer prevalence in Central Europe: The EROPREVAL Study",
abstract = "Background: Information on cancer prevalence is either absent or largely unavailable for central European countries. Materials and methods: Austria, Germany, The Netherlands, Poland, Slovakia, Slovenia and Switzerland cover a population of 13 million inhabitants. Cancer registries in these countries supplied incidence and survival data for 465 000 cases of cancer. The prevalence of stomach, colon, rectum, lung, breast, cervix uteri, corpus uteri and prostate cancer, as well as skin melanoma, Hodgkin's disease, leukaemia and all malignant neoplasms combined was estimated for the end of 1992. Results: A large heterogeneity was observed within central European countries. For all cancers combined, estimates ranged from 730 per 100 000 in Poland (men) to 3350 per 100 000 in Germany (women). Overall cancer prevalence was the highest in Germany and Switzerland, and the lowest in Poland and Slovenia. In Slovakia, prevalence was higher than average for men and lower than average for women. This was observed for almost all ages. As shown by incidence data, breast cancer was the most frequent malignancy among women in all countries. Among men, prostate cancer was the leading malignancy in Germany, Austria and Switzerland, and lung cancer was the major cancer in Slovenia, Slovakia and Poland. The Netherlands had a high prevalence of both prostate and lung cancer. Time-related magnitude of prevalence within each country and the variability of such proportions across the countries has been estimated and cancer prevalence is given by time since diagnosis (1 year, 1-5 years, 5-10 years, >10 years) for each site. The weight of 1-year prevalence (248 per 100 000 among men and 253 per 100 000 among women) was 10 years before), reflecting long-term survival, and number of people considered as cured from cancer were 490 per 100 000 for men and 1028 per 100 000 for women, with a range between 26{\%} (The Netherlands, men) and 50{\%} (Slovakia, women). Conclusion: It is clear from observing countries in Central Europe, that high cancer prevalence is associated with well-developed economies. This burden of cancer could be interpreted as a paradoxical effect of better treatments and thereby survival. It could also be taken as a sign for not being satisfied with the advances in treating patients diagnosed with cancer, and for supporting more primary prevention.",
keywords = "Cancer registries, Central Europe, Prevalence",
author = "Lutz, {J. M.} and S. Francisci and E. Mugno and M. Usel and V. Pompe-Kirn and Coebergh, {J. W.} and M. Bieslka-Lasota and W. Oberaigner and H. Storm and G. Engholm and T. Aareleid and T. Hakulinen and G. H{\'e}delin and H. Lefevre and J. Mace-Lesec'h and J. Faivre and G. Chaplain and Carli, {P. M.} and P. Arveux and J. Est{\`e}ve and M. Colonna and N. Raverdy and P. Jun and J. Michaelis and H. Ziegler and C. Stegmaier and H. Tulinius and R. Capocaccia and I. Corazziari and {De Angelis}, R. and S. Francisci and S. Hartley and F. Valente and A. Verdecchia and A. Zappone and F. Berrino and G. Gatta and A. Micheli and E. Mugno and M. Sant and P. Crosignani and E. Conti and M. Vercelli and C. Casella and A. Puppo and M. Federico and {Ponz De Leon}, M. and {De Lisi}, V. and R. Zanetti and C. Magnani and L. Gaf{\`a} and F. Falcini and E. Paci and E. Crocetti and S. Guzzinati and J. Rachtan and M. Bielska-Lasota and I. Plesko and V. Pompe-Kirn and I. Izarzugaza and A. Izquierdo and C. Martinez-Garcia and I. Garau and E. Ardanaz and C. Moreno and J. Galceran and V. Moreno and T. M{\"o}ller and H. Anderson and J. Torhorst and C. Bouchardy and Lutz, {J. M.} and M. Usel and Dowd, {J. E.} and Coebergh, {J. W W} and M. Janssen-Heijnen and Damhuis, {R. A M} and R. Black and V. Harris and D. Stockton and Davies, {T. W.} and Coleman, {M. P.} and S. Harris and Williams, {E. M I} and D. Forman and R. Iddenden and Quinn, {M. J.} and M. Roche and J. Smith and H. Moller and P. Silcocks and G. Lawrence and K. Hemmings",
year = "2003",
month = "2",
day = "1",
doi = "10.1093/annonc/mdg059",
language = "English",
volume = "14",
pages = "313--322",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "2",

}

TY - JOUR

T1 - Cancer prevalence in Central Europe

T2 - The EROPREVAL Study

AU - Lutz, J. M.

AU - Francisci, S.

AU - Mugno, E.

AU - Usel, M.

AU - Pompe-Kirn, V.

AU - Coebergh, J. W.

AU - Bieslka-Lasota, M.

AU - Oberaigner, W.

AU - Storm, H.

AU - Engholm, G.

AU - Aareleid, T.

AU - Hakulinen, T.

AU - Hédelin, G.

AU - Lefevre, H.

AU - Mace-Lesec'h, J.

AU - Faivre, J.

AU - Chaplain, G.

AU - Carli, P. M.

AU - Arveux, P.

AU - Estève, J.

AU - Colonna, M.

AU - Raverdy, N.

AU - Jun, P.

AU - Michaelis, J.

AU - Ziegler, H.

AU - Stegmaier, C.

AU - Tulinius, H.

AU - Capocaccia, R.

AU - Corazziari, I.

AU - De Angelis, R.

AU - Francisci, S.

AU - Hartley, S.

AU - Valente, F.

AU - Verdecchia, A.

AU - Zappone, A.

AU - Berrino, F.

AU - Gatta, G.

AU - Micheli, A.

AU - Mugno, E.

AU - Sant, M.

AU - Crosignani, P.

AU - Conti, E.

AU - Vercelli, M.

AU - Casella, C.

AU - Puppo, A.

AU - Federico, M.

AU - Ponz De Leon, M.

AU - De Lisi, V.

AU - Zanetti, R.

AU - Magnani, C.

AU - Gafà, L.

AU - Falcini, F.

AU - Paci, E.

AU - Crocetti, E.

AU - Guzzinati, S.

AU - Rachtan, J.

AU - Bielska-Lasota, M.

AU - Plesko, I.

AU - Pompe-Kirn, V.

AU - Izarzugaza, I.

AU - Izquierdo, A.

AU - Martinez-Garcia, C.

AU - Garau, I.

AU - Ardanaz, E.

AU - Moreno, C.

AU - Galceran, J.

AU - Moreno, V.

AU - Möller, T.

AU - Anderson, H.

AU - Torhorst, J.

AU - Bouchardy, C.

AU - Lutz, J. M.

AU - Usel, M.

AU - Dowd, J. E.

AU - Coebergh, J. W W

AU - Janssen-Heijnen, M.

AU - Damhuis, R. A M

AU - Black, R.

AU - Harris, V.

AU - Stockton, D.

AU - Davies, T. W.

AU - Coleman, M. P.

AU - Harris, S.

AU - Williams, E. M I

AU - Forman, D.

AU - Iddenden, R.

AU - Quinn, M. J.

AU - Roche, M.

AU - Smith, J.

AU - Moller, H.

AU - Silcocks, P.

AU - Lawrence, G.

AU - Hemmings, K.

PY - 2003/2/1

Y1 - 2003/2/1

N2 - Background: Information on cancer prevalence is either absent or largely unavailable for central European countries. Materials and methods: Austria, Germany, The Netherlands, Poland, Slovakia, Slovenia and Switzerland cover a population of 13 million inhabitants. Cancer registries in these countries supplied incidence and survival data for 465 000 cases of cancer. The prevalence of stomach, colon, rectum, lung, breast, cervix uteri, corpus uteri and prostate cancer, as well as skin melanoma, Hodgkin's disease, leukaemia and all malignant neoplasms combined was estimated for the end of 1992. Results: A large heterogeneity was observed within central European countries. For all cancers combined, estimates ranged from 730 per 100 000 in Poland (men) to 3350 per 100 000 in Germany (women). Overall cancer prevalence was the highest in Germany and Switzerland, and the lowest in Poland and Slovenia. In Slovakia, prevalence was higher than average for men and lower than average for women. This was observed for almost all ages. As shown by incidence data, breast cancer was the most frequent malignancy among women in all countries. Among men, prostate cancer was the leading malignancy in Germany, Austria and Switzerland, and lung cancer was the major cancer in Slovenia, Slovakia and Poland. The Netherlands had a high prevalence of both prostate and lung cancer. Time-related magnitude of prevalence within each country and the variability of such proportions across the countries has been estimated and cancer prevalence is given by time since diagnosis (1 year, 1-5 years, 5-10 years, >10 years) for each site. The weight of 1-year prevalence (248 per 100 000 among men and 253 per 100 000 among women) was 10 years before), reflecting long-term survival, and number of people considered as cured from cancer were 490 per 100 000 for men and 1028 per 100 000 for women, with a range between 26% (The Netherlands, men) and 50% (Slovakia, women). Conclusion: It is clear from observing countries in Central Europe, that high cancer prevalence is associated with well-developed economies. This burden of cancer could be interpreted as a paradoxical effect of better treatments and thereby survival. It could also be taken as a sign for not being satisfied with the advances in treating patients diagnosed with cancer, and for supporting more primary prevention.

AB - Background: Information on cancer prevalence is either absent or largely unavailable for central European countries. Materials and methods: Austria, Germany, The Netherlands, Poland, Slovakia, Slovenia and Switzerland cover a population of 13 million inhabitants. Cancer registries in these countries supplied incidence and survival data for 465 000 cases of cancer. The prevalence of stomach, colon, rectum, lung, breast, cervix uteri, corpus uteri and prostate cancer, as well as skin melanoma, Hodgkin's disease, leukaemia and all malignant neoplasms combined was estimated for the end of 1992. Results: A large heterogeneity was observed within central European countries. For all cancers combined, estimates ranged from 730 per 100 000 in Poland (men) to 3350 per 100 000 in Germany (women). Overall cancer prevalence was the highest in Germany and Switzerland, and the lowest in Poland and Slovenia. In Slovakia, prevalence was higher than average for men and lower than average for women. This was observed for almost all ages. As shown by incidence data, breast cancer was the most frequent malignancy among women in all countries. Among men, prostate cancer was the leading malignancy in Germany, Austria and Switzerland, and lung cancer was the major cancer in Slovenia, Slovakia and Poland. The Netherlands had a high prevalence of both prostate and lung cancer. Time-related magnitude of prevalence within each country and the variability of such proportions across the countries has been estimated and cancer prevalence is given by time since diagnosis (1 year, 1-5 years, 5-10 years, >10 years) for each site. The weight of 1-year prevalence (248 per 100 000 among men and 253 per 100 000 among women) was 10 years before), reflecting long-term survival, and number of people considered as cured from cancer were 490 per 100 000 for men and 1028 per 100 000 for women, with a range between 26% (The Netherlands, men) and 50% (Slovakia, women). Conclusion: It is clear from observing countries in Central Europe, that high cancer prevalence is associated with well-developed economies. This burden of cancer could be interpreted as a paradoxical effect of better treatments and thereby survival. It could also be taken as a sign for not being satisfied with the advances in treating patients diagnosed with cancer, and for supporting more primary prevention.

KW - Cancer registries

KW - Central Europe

KW - Prevalence

UR - http://www.scopus.com/inward/record.url?scp=0345269297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0345269297&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdg059

DO - 10.1093/annonc/mdg059

M3 - Article

VL - 14

SP - 313

EP - 322

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 2

ER -